Summary
Sparteine sulphate, given i.v. as a bolus of 15 mg/ml plus 90 mg in 0.9% NaCl 100 ml over 60 min, increases plasma insulin and decreases plasma glucose and adrenaline in non-insulin dependent (Type II) diabetic subjects. The hypoglycaemic effect was also evident in the presence of a high plasma glucose level produced by Biostator changing glucose infusion from 20.2±2.8 to 26.4±4.2 mg · kg−1 · min−1 (p<0.01), and it was potentiated by simultaneous infusion of arginine.
No additional effect of sparteine on the peripheral sensitivity to insulin were detected by the euglycaemic, hyperinsulinaemic glucose clamp technique, as the glucose infusion rate (3.1±0.8 vs 2.6±1.2 mg · kg−1 · min−1) was not statistically significant different in the last 60 min of the experiment.
It is concluded that sparteine sulphate enhances β-cell secretion, causing a fall in the plasma glucose concentration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Fronzo RA, Simonson MC (1984) Oral sulfonylurea agents suppress hepatic glucose production in non-insulin dependent diabetic individuals. Diabetes Care 7 [Suppl 1]: 72–80
Mandarino LJ, Gerich JE (1984) Prolonged sulfonylureas administration decrease insulin resistance and increase insulin secretion in non-insulin dependent diabetes mellitus. Evidence for improved insulin action at postreceptor site in hepatic as well as extra-hepatic tissue. Diabetes Care 7 [Suppl 1]: 89–99
Paolisso G, Nenquin M, Schmeer W, Mathot F, Meissner HP, Henquin JC (1985) Sparteine sulphate increase insulin release by decreasing the K+ permeability of the β-cell membrane. Biochem Pharmacol 34: 2355–2361
Sgambato S, Passariello N, Paolisso G, Bisesti V, Tesauro P (1986) Effect of sparteine sulphate on insulin secretion in normal man. Horm Metab Res 18: 686–688
Sgambato S, Paolisso G, Passariello G, Varricchio M, D'Onofrio F (1987) Sparteine sulphate effects upon basal and nutrients induced insulin and glucagon secretion in normal man. Eur J Clin Pharmacol 32: 477–480
Paolisso G, Sgambato S, Passariello N, Pizza G, Varricchio M, Torella R, D'Onofrio F (1987) Effects of sparteine sulphate on glucagon secretion in insulin dependent (Type 1) diabetic subjecats. Horm Metab Res 19: 389–390
De Fronzo R, Tobin J, Andreas R (1979) Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 273: E214–223
Verdonk CA, Rizza RA, Westland RE, Nelson RL, Gerich JE (1980) Glucose clamp using the Biostator GCIIS Horm Metab Res 12: 133–135
De Prado G, Zurcher G (1979) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within fentomole range. Life Sci 19: 1161–1174
Henquin JC, Meissner HP (1984) Significance of ionic fluxes and changes in membrane potential for stimulus-secretion coupling in pancreatic β-cells Experientia 40: 1043–1052
Henquin JC, Meissner HP (1982) Opposite effects of tolbutamide and diazoxide on 86Rb flux and membrane potential in pancreatic β-cell. Biochem Pharmacol 31: 1407–1415
Paolisso G, Nenquin M, Meissner HP, Henquin JC (1985) The effects of cesium chloride on insulin release, inoic flux and membrane potential in pancreatic β-cell. Biochem Biophys Acta 844: 200–208
Rizza R, Haymond M, Cryer P, Gerich JE (1980) Differential effects of epinephrine on glucose production and disposal in man. Am J Physiol 237: E356–362
Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG (1984) Influence of hyperglycemia on insulin's in Vivo effects in Type II diabetes. J Clin Invest 73: 664–672
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paolisso, G., Sgambato, S., Passariello, N. et al. Plasma glucose lowering effect of spartein sulphate infusion in non-insulin dependent (Type 2) diabetic subjects. Eur J Clin Pharmacol 34, 227–232 (1988). https://doi.org/10.1007/BF00540948
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00540948